Bottom line
Is PASSX a good fund? The bottom line
PASSX is the T. Rowe Price Small-Cap Stock Fund-Advisor Class share class of T. Rowe Price Small-Cap Stock Fund, Inc., an actively managed small-cap mutual fund from T. Rowe Price.
Its expense ratio is 1.17% — about $117 a year on every $10,000 invested, more expensive than 67% of small-cap funds we track.
It returned +8.0% over one year, +4.7% a year over five years, +10.6% a year over ten (as of Dec 31, 2025, per its prospectus).
With $9.3 billion in net assets and 326 holdings, its largest position is Liberty Live Holdings-c (2.5%) and the top 10 make up 16% of the portfolio.
What stands out
- Broadly diversified (326 holdings)
What to watch
- 12b-1 marketing fee of 0.25% a year
Updated Nov 19, 2026
What PASSX invests in
The fund seeks to provide long-term capital growth by investing primarily in stocks of small companies.
The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in stocks of small companies. Any derivatives that provide exposure to the investment focus suggested by the funds name, or to one or more market risk factors associated with the investment focus suggested by the funds name, are counted (as applicable) toward compliance with the funds 80% investment policy. The fund defines a small-cap company as a company whose market capitalization falls below the maximum market capitalization in the Russell 2000 Index, MSCI USA Small Cap Index, or MSCI World Small Cap Index (after systematically removing any companies that cannot reasonably be considered a small-cap company from the high end of the range of each index). The market capitalizations of the companies in the indexes change over time and the indexes are periodically reconstituted to…
From the fund's prospectus (filed Feb 25, 2026).
PASSX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| PASSX | +8.0% | +4.7% | +10.6% |
| Small-Cap median | +7.6% | +7.0% | +9.2% |
Source: Fund prospectus, as of Dec 31, 2025
What PASSX costs
On a $10,000 investment, PASSX's 1.17% expense ratio costs about $117 a year. The prospectus estimates $1,420 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.
PASSX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Liberty Live Holdings-c | 2.54% |
| 2 | Lattice Semiconductor Corp | 2.04% |
| 3 | Vse Corp | 1.82% |
| 4 | Dyne Therapeutics Inc | 1.67% |
| 5 | Immunome Inc | 1.64% |
| 6 | Loar Holdings Inc | 1.47% |
| 7 | Brightspring Health Services | 1.34% |
| 8 | Dianthus Therapeutics Inc | 1.21% |
| 9 | Esab Corp | 1.14% |
| 10 | Golar Lng Ltd | 1.13% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 16% of the fund. See all top 25 holdings and asset mix →